Multiple presentations from Mustang Bio
NEW YORK—Mustang Bio Inc. debuted preclinical and Phase 1 data at the recent 21st Annual Meeting and Education Day of the Society for Neuro-Oncology for its MB-101 (IL13Rα2-specific Chimeric Antigen Receptor–engineered CAR T cells). The preclinical data was presented in a talk titled “Development of murine IL13Rα2-targeted CAR T cells (mIL13BBζ) for assessment of CAR T cell therapy in syngeneic glioma models.” This work focused on a mouse IL13Rα2-targeted CAR T cell platform developed to assess variables that can affect the efficacy of CAR T cell therapy. IL13Rα2 represents a promising target for CAR T cell therapy given its minor expression in normal tissue and over-expression on the surface of most glioblastomas. Phase 1 data of the CAR T cells in glioblastoma were also presented, showing the treatment to be well tolerated with mild side effects and capable of triggering a potent antitumor response.